Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7251 results

Sort By:

A Phase 2 Open Label Study of BA3021 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Study ID: NCT05271604
Start Date: 2022-12-13
End Date: 2026-12
Study Type

Interventional

Study Phase

Phase2

No. of Participants

290

Intervention / Treatment

Ozuriftam vedotin

Pembrolizumab

Evalstotug (BA3071)

Cetuximab

Sponsor

Bioatla, Inc.

Source: clinicaltrials.gov

Share:
Add to list

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple Myeloma

Study ID: NCT04942067
Start Date: 2021-12-23
End Date: 2024-12-01
Study Type

Interventional

Study Phase

Phase2

No. of Participants

108

Intervention / Treatment

APG-2575+ Pd

APG-2575 + DRd

Sponsor

Ascentage Pharma Group Inc.

Source: clinicaltrials.gov

Share:
Add to list

A Randomized Controlled Trial of Inhaled Tranexamic Acid for the Treatment of Pulmonary Hemorrhage in Cancer Patients

Study ID: NCT05053867
Start Date: 2022-10-14
End Date: 2025-07-31
Study Type

Interventional

Study Phase

Phase3

No. of Participants

60

Intervention / Treatment

tranexamic acid

Usual Care

Sponsor

M.D. Anderson Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Study ID: NCT06346067
Start Date: 2024-04-29
End Date: 2028-12
Study Type

Interventional

Study Phase

Phase3

No. of Participants

470

Intervention / Treatment

Hurgefenib

Dacarbazine

Temozolomide

Trametinib

Sponsor

Erasca, Inc.

Source: clinicaltrials.gov

Share:
Add to list

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Study ID: NCT03606967
Start Date: 2021-04-13
End Date: 2025-11-30
Study Type

Interventional

Study Phase

Phase2

No. of Participants

70

Intervention / Treatment

Biopsy Procedure

Biospecimen Collection

Carboplatin

Computed Tomography

Durvalumab

Gemcitabine Hydrochloride

Magnetic Resonance Imaging

Nab-paclitaxel

Personalized Synthetic Long Peptide Vaccine

Poly ICLC

Sacituzumab Govitan

Tremelimumab

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial

Study ID: NCT05554367
Start Date: 2023-12-13
End Date: 2026-08-26
Study Type

Interventional

Study Phase

Phase2

No. of Participants

199

Intervention / Treatment

Binimetinib

Biopsy Procedure

Biospecimen Collection

Bone Scan

Computed Tomography

Magnetic Resonance Imaging

Palbociclib

Sponsor

National Cancer Institute (NCI)

Source: clinicaltrials.gov

Share:
Add to list

GRID Therapy for Extremity Soft Tissue Sarcoma

Study ID: NCT06073067
Start Date: 2023-11-09
End Date: 2026-08-15
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

20

Intervention / Treatment

GRID therapy

Sponsor

UNC Lineberger Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis

Study ID: NCT05201404
Start Date: 2023-03-15
End Date: 2026-10
Study Type

Interventional

Study Phase

Phase3

No. of Participants

471

Intervention / Treatment

Namodenoson

Placebo

Sponsor

Can-Fite BioPharma

Source: clinicaltrials.gov

Share:
Add to list

Telehealth Visits to Discuss Advanced Directives for Patients Newly Diagnosed With High Grade Glioma

Study ID: NCT04543201
Start Date: 2021-08-26
End Date: 2026-07-31
Study Type

Interventional

Study Phase

Not Applicable

No. of Participants

50

Intervention / Treatment

Early START visit using checklist over telephone or zoom

Sponsor

University of Rochester

Source: clinicaltrials.gov

Share:
Add to list

Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)

Study ID: NCT02494167
Start Date: 2016-02
End Date: 2027-02
Study Type

Interventional

Study Phase

Phase1

No. of Participants

44

Intervention / Treatment

MultiTAA-specific T cells

Sponsor

Baylor College of Medicine

Source: clinicaltrials.gov

Share:
Add to list